HAYWARD, Calif., Feb. 19, 2015 /PRNewswire/ -- Anthera
Pharmaceuticals, Inc. (NASDAQ:ANTH), announced today that
Paul F. Truex, President and Chief
Executive Officer, will present a corporate update on the progress
of the Company's development programs at the 35th Annual
Cowen & Company Health Care Conference.
Anthera will present from 10:00 – 10:30
EST on Wednesday, March
4th in Salon H on the 4th floor of the
Boston Marriott Copley Place. A breakout session will be held from
10:40 – 11:10 EST in Salon I of the
4th floor.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing products to treat serious and
life-threatening diseases, including systemic lupus erythematosus,
IgA nephropathy, and exocrine pancreatic insufficiency due to
cystic fibrosis.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on Anthera's expectations as
of the date of this press release and are subject to certain risks
and uncertainties that could cause actual results to differ
materially as set forth in Anthera's public filings with the SEC,
including Anthera's Annual Report on Form 10-K for the year ended
December 31, 2013. Anthera
disclaims any intent or obligation to update any forward-looking
statements, whether because of new information, future events or
otherwise, except as required by applicable law.
CONTACT: Dennis Lutz of Anthera
Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anthera-pharmaceuticals-to-present-at-cowen--co-healthcare-conference-300038597.html
SOURCE Anthera Pharmaceuticals, Inc.